AI Engines For more Details: Perplexity Kagi Labs You
Reduction of Intraocular Pressure: Methazolamide helps lower intraocular pressure by decreasing the production of aqueous humor in the eye. By reducing intraocular pressure, the medication can slow down the progression of optic nerve damage and vision loss associated with glaucoma.
Treatment of Glaucoma: Methazolamide is primarily prescribed to individuals with open-angle glaucoma, a common form of glaucoma where the drainage angle of the eye remains open but fluid drainage is inadequate. By reducing intraocular pressure, methazolamide helps manage the condition and prevent further vision loss.
Adjunctive Therapy: In addition to being used as a standalone treatment for glaucoma, methazolamide may also be prescribed as adjunctive therapy alongside other medications or interventions to further lower intraocular pressure and improve treatment outcomes.
Side Effects: Like all medications, methazolamide can cause side effects, although not everyone will experience them. Common side effects may include gastrointestinal disturbances (such as nausea, vomiting, diarrhea), frequent urination, loss of appetite, taste alterations, and tingling sensations in the extremities. Less commonly, methazolamide may cause more serious side effects such as electrolyte imbalances, metabolic acidosis, blood disorders, and kidney stones.
Contraindications: Methazolamide is contraindicated in individuals with a known allergy to sulfonamide medications, severe kidney or liver disease, adrenal gland failure, and certain electrolyte imbalances. It should be used with caution in individuals with respiratory or metabolic acidosis, severe chronic obstructive pulmonary disease (COPD), or electrolyte abnormalities.
| Rank | Probiotic | Impact |
|---|
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
| 📓 Direct Citations | 👪👶 Indirect Citations | Taxonomy | Rank | Effect |
|---|---|---|---|---|
| 0 | 1 | Roseburia | genus | Decreases |
| 0 | 1 | Ruminococcus | genus | Decreases |
| 0 | 1 | Coprococcus | genus | Decreases |
| 0 | 1 | Lachnospira | genus | Decreases |
| 0 | 1 | Streptococcus | genus | Decreases |
| 1 | 0 | Coprococcus comes | species | Decreases |
| 1 | 0 | Ruminococcus bromii | species | Decreases |
| 1 | 0 | Roseburia intestinalis | species | Decreases |
| 1 | 0 | Streptococcus salivarius | species | Decreases |
| 1 | 0 | Lachnospira eligens | species | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Acne | 0.3 | 0.3 | |
| ADHD | 1.1 | 0.3 | 2.67 |
| Age-Related Macular Degeneration and Glaucoma | 0.5 | 0.5 | |
| Allergic Rhinitis (Hay Fever) | 0.3 | 0.3 | 0 |
| Allergies | 0.3 | 0.5 | -0.67 |
| Allergy to milk products | 0.6 | 0.6 | |
| Alzheimer's disease | 0.3 | 1.9 | -5.33 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.3 | 0.3 | 0 |
| Ankylosing spondylitis | 0.6 | 0.6 | 0 |
| Anorexia Nervosa | 0.6 | 1.4 | -1.33 |
| Antiphospholipid syndrome (APS) | 0.5 | 0.5 | |
| Asthma | 1.2 | 0.8 | 0.5 |
| Atherosclerosis | 0.3 | 0.7 | -1.33 |
| Atrial fibrillation | 1.2 | 1.2 | |
| Autism | 1.4 | 1.8 | -0.29 |
| Autoimmune Disease | 0.3 | 0.5 | -0.67 |
| Barrett esophagus cancer | 0.3 | -0.3 | |
| Biofilm | 0.3 | 0.3 | |
| Bipolar Disorder | 0.3 | 1.1 | -2.67 |
| Brain Trauma | 0.3 | 0.8 | -1.67 |
| Breast Cancer | 0.3 | 0.3 | 0 |
| Carcinoma | 0.6 | 0.3 | 1 |
| Celiac Disease | 0.5 | 0.6 | -0.2 |
| Cerebral Palsy | 0.3 | 0.8 | -1.67 |
| Chronic Fatigue Syndrome | 0.8 | 1.5 | -0.88 |
| Chronic Kidney Disease | 1.1 | -1.1 | |
| Chronic Lyme | 0.5 | -0.5 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.7 | 1.4 | -1 |
| Chronic Urticaria (Hives) | 0.3 | 0.3 | |
| Coagulation / Micro clot triggering bacteria | 0.3 | 1.1 | -2.67 |
| Cognitive Function | 1.1 | 0.8 | 0.38 |
| Colorectal Cancer | 1.2 | 0.5 | 1.4 |
| Constipation | 0.6 | 0.5 | 0.2 |
| Coronary artery disease | 0.6 | 0.8 | -0.33 |
| COVID-19 | 0.6 | 2 | -2.33 |
| Crohn's Disease | 1.4 | 1.5 | -0.07 |
| cystic fibrosis | 0.5 | -0.5 | |
| deep vein thrombosis | 1.1 | 1.1 | 0 |
| Denture Wearers Oral Shifts | 0.4 | 0.4 | |
| Depression | 1.7 | 2.5 | -0.47 |
| Dermatomyositis | 0.3 | 0.3 | |
| Eczema | 0.3 | 0.4 | -0.33 |
| Endometriosis | 0.6 | 1.4 | -1.33 |
| Eosinophilic Esophagitis | 0.3 | -0.3 | |
| Epilepsy | 0.3 | 0.3 | |
| Fibromyalgia | 0.5 | 0.6 | -0.2 |
| Functional constipation / chronic idiopathic constipation | 1.4 | 1.1 | 0.27 |
| gallstone disease (gsd) | 0.3 | 0.5 | -0.67 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.6 | -0.6 | |
| Generalized anxiety disorder | 0.6 | 1.1 | -0.83 |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 0.6 | 0.6 | 0 |
| Graves' disease | 0.3 | 1.4 | -3.67 |
| Gulf War Syndrome | 0.6 | 0.6 | |
| Halitosis | 0.3 | 0.3 | 0 |
| Hashimoto's thyroiditis | 0.8 | 0.3 | 1.67 |
| Heart Failure | 0.9 | 0.8 | 0.13 |
| Hidradenitis Suppurativa | 0.6 | 0.6 | |
| High Histamine/low DAO | 0.5 | 0.3 | 0.67 |
| hyperglycemia | 0.1 | 0.1 | |
| hypertension (High Blood Pressure | 0.9 | 1.5 | -0.67 |
| Hypothyroidism | 0.3 | -0.3 | |
| IgA nephropathy (IgAN) | 0.6 | 0.6 | 0 |
| Inflammatory Bowel Disease | 0.4 | 2.1 | -4.25 |
| Insomnia | 0.7 | 1.4 | -1 |
| Intelligence | 0.3 | 0.3 | |
| Intracranial aneurysms | 0.3 | 0.3 | 0 |
| Irritable Bowel Syndrome | 1.1 | 1.7 | -0.55 |
| ischemic stroke | 0.6 | 0.5 | 0.2 |
| Liver Cirrhosis | 1.5 | 1.4 | 0.07 |
| Long COVID | 1.2 | 1.7 | -0.42 |
| Low bone mineral density | 1.1 | -1.1 | |
| Lung Cancer | 0.3 | -0.3 | |
| Mast Cell Issues / mastitis | 0.3 | 0.6 | -1 |
| ME/CFS with IBS | 0.3 | 0.6 | -1 |
| ME/CFS without IBS | 0.3 | 0.3 | |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 0.3 | 0.5 | -0.67 |
| Metabolic Syndrome | 1.4 | 1.4 | 0 |
| Mood Disorders | 1.7 | 2.3 | -0.35 |
| multiple chemical sensitivity [MCS] | 0.4 | 0.4 | |
| Multiple Sclerosis | 0.7 | 1.5 | -1.14 |
| Multiple system atrophy (MSA) | 0.3 | -0.3 | |
| myasthenia gravis | 0.3 | 0.5 | -0.67 |
| neuropathic pain | 0.8 | -0.8 | |
| Neuropathy (all types) | 0.3 | 0.5 | -0.67 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.3 | 0.3 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 1.4 | 1.4 | 0 |
| Obesity | 1.7 | 1.8 | -0.06 |
| obsessive-compulsive disorder | 0.8 | 0.6 | 0.33 |
| Osteoarthritis | 0.3 | 0.6 | -1 |
| Osteoporosis | 0.8 | 0.3 | 1.67 |
| pancreatic cancer | 0.3 | 0.3 | 0 |
| Parkinson's Disease | 1.4 | 1.9 | -0.36 |
| Polycystic ovary syndrome | 1.7 | 1.4 | 0.21 |
| Postural orthostatic tachycardia syndrome | 0.3 | -0.3 | |
| primary biliary cholangitis | 0.3 | 0.3 | 0 |
| Primary sclerosing cholangitis | 0.3 | 0.6 | -1 |
| Psoriasis | 0.6 | 0.8 | -0.33 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 2 | 0.8 | 1.5 |
| Rosacea | 0.3 | 0.5 | -0.67 |
| Schizophrenia | 1.2 | 1.4 | -0.17 |
| scoliosis | 0.3 | 0.4 | -0.33 |
| Sjögren syndrome | 0.3 | 0.3 | |
| Sleep Apnea | 0.9 | 1.1 | -0.22 |
| Slow gastric motility / Gastroparesis | 0.3 | 0.3 | |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.6 | 0.6 | |
| Stress / posttraumatic stress disorder | 0.5 | 0.8 | -0.6 |
| Systemic Lupus Erythematosus | 0.6 | 1.1 | -0.83 |
| Tic Disorder | 0.6 | 0.6 | |
| Tourette syndrome | 0.3 | 0.3 | |
| Type 1 Diabetes | 0.9 | 1.4 | -0.56 |
| Type 2 Diabetes | 1.4 | 1.4 | 0 |
| Ulcerative colitis | 0.6 | 1.1 | -0.83 |
| Unhealthy Ageing | 0.6 | 0.8 | -0.33 |
| Vitiligo | 0.9 | 0.6 | 0.5 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]
